{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:05:10Z","timestamp":1772762710399,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T00:00:00Z","timestamp":1513814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Novartis Vaccines Division"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.jinf.2017.12.005","type":"journal-article","created":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T12:54:39Z","timestamp":1513342479000},"page":"258-269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Antibody persistence and booster responses 24\u201336 months after different 4CMenB vaccination schedules in infants and children: A randomised trial"],"prefix":"10.1016","volume":"76","author":[{"given":"Federico","family":"Martin\u00f3n-Torres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Carmona Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00f3bert","family":"Simk\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Infante Marquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7618-6057","authenticated-orcid":false,"given":"Josep-Lluis","family":"Arimany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Gimenez-Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Antonio","family":"Couceiro Gianzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9va","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Rojo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huajun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiranjiwi","family":"Bhusal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Toneatto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2017.12.005_bib0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metr"},{"key":"10.1016\/j.jinf.2017.12.005_bib0015","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jadohealth.2016.03.041","article-title":"Deciphering the burden of meningococcal disease: conventional and under-recognized elements","volume":"59","author":"Martinon-Torres","year":"2016","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.jinf.2017.12.005_bib0020","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2174\/1871526515999150320155614","article-title":"Complications of serogroup B meningococcal disease in survivors: a review","volume":"14","author":"Dastouri","year":"2014","journal-title":"Infect Disord Drug Targets"},{"key":"10.1016\/j.jinf.2017.12.005_bib0025","author":"World Health Organization"},{"key":"10.1016\/j.jinf.2017.12.005_bib0030","author":"European Centre for Disease Prevention and Control"},{"issue":"Suppl","key":"10.1016\/j.jinf.2017.12.005_bib0035","first-page":"S1","article-title":"Summary of National Surveillance Data on Vaccine Preventable Diseases in Australia, 2008\u20132011","volume":"40","author":"Dey","year":"2016","journal-title":"Commun Dis Intell Q Rep"},{"key":"10.1016\/j.jinf.2017.12.005_bib0040","author":"Robinson"},{"key":"10.1016\/j.jinf.2017.12.005_bib0045","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.15585\/mmwr.mm6441a3","article-title":"Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the advisory committee on immunization practices, 2015","volume":"64","author":"MacNeil","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jinf.2017.12.005_bib0050","article-title":"A prolonged outbreak of invasive meningococcal disease in an extended Irish Traveller family across three Health Service Executive (HSE) areas in Ireland, 2010 to 2013","volume":"20","author":"O'Connor","year":"2015","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jinf.2017.12.005_bib0055","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/j.1469-0691.2006.01521.x","article-title":"Conventional and molecular investigation of meningococcal isolates in relation to two outbreaks in the area of Athens, Greece","volume":"12","author":"Tzanakaki","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jinf.2017.12.005_bib0060","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/1757913912439928","article-title":"Public health action and mass chemoprophylaxis in response to a small meningococcal infection outbreak at a nursery in the West Midlands, England","volume":"133","author":"Stewart","year":"2013","journal-title":"Perspect Public Health"},{"key":"10.1016\/j.jinf.2017.12.005_bib0065","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES2014.19.44.20949","article-title":"Four-month outbreak of invasive meningococcal disease caused by a rare serogroup B strain, identified through the use of molecular PorA subtyping, England, 2013","volume":"19","author":"Chatt","year":"2014","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jinf.2017.12.005_bib0070","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1136\/archdischild-2011-301074","article-title":"A cluster of four cases of meningococcal disease in a single nuclear family","volume":"97","author":"Acheson","year":"2012","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jinf.2017.12.005_bib0075","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2051013616681365","article-title":"Multicomponent meningococcal B vaccination (4CMenB) of adolescents and college students in the United States","volume":"5","author":"Banzhoff","year":"2017","journal-title":"Ther Adv Vaccines"},{"key":"10.1016\/j.jinf.2017.12.005_bib0080","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1542\/peds.2014-4015","article-title":"First use of a serogroup B meningococcal vaccine in the US in response to a university outbreak","volume":"135","author":"McNamara","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.jinf.2017.12.005_bib0085","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.vaccine.2015.11.057","article-title":"Clinical experience with the meningococcal B vaccine, Bexsero(\u00ae): prospects for reducing the burden of meningococcal serogroup B disease","volume":"34","author":"Watson","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2017.12.005_bib0090","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/21645515.2017.1264750","article-title":"Meningococcal serogroup B vaccines: estimating breadth of coverage","volume":"13","author":"Donald","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jinf.2017.12.005_bib0095","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2017.12.005_bib0100","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jinf.2017.12.005_bib0105","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/INF.0b013e3181f59f6d","article-title":"Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial","volume":"29","author":"Snape","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jinf.2017.12.005_bib0110","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2017.12.005_bib0115","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1097\/INF.0000000000001056","article-title":"Persistence of bactericidal antibodies after infant serogroup B meningococcal immunization and booster dose response at 12, 18 or 24 months of age","volume":"35","author":"Snape","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jinf.2017.12.005_bib0120","author":"Novartis.com"},{"key":"10.1016\/j.jinf.2017.12.005_bib0125","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/21645515.2015.1091131","article-title":"Vaccines for the prevention of meningococcal capsular group B disease: what have we recently learned?","volume":"12","author":"Findlow","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jinf.2017.12.005_bib0130","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jinf.2015.09.035","article-title":"The introduction of the meningococcal B (MenB) vaccine (Bexsero\u00ae) into the national infant immunisation programme\u2014new challenges for public health","volume":"71","author":"Ladhani","year":"2015","journal-title":"J Infect"},{"key":"10.1016\/j.jinf.2017.12.005_bib0135","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1016\/S0140-6736(16)31921-3","article-title":"Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study","volume":"388","author":"Parikh","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2017.12.005_bib0140","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.vaccine.2017.05.023","article-title":"Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: immunogenicity and safety results from a randomised open-label phase 3b trial","volume":"35","author":"Martinon-Torres","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2017.12.005_bib0145","doi-asserted-by":"crossref","first-page":"E715","DOI":"10.1503\/cmaj.130257","article-title":"Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose","volume":"185","author":"Snape","year":"2013","journal-title":"CMAJ"},{"key":"10.1016\/j.jinf.2017.12.005_bib0150","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1016\/j.vaccine.2015.06.079","article-title":"Meningococcal serogroup B vaccine (4CMenB): booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children","volume":"33","author":"Vesikari","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2017.12.005_bib0155","doi-asserted-by":"crossref","first-page":"E215","DOI":"10.1503\/cmaj.141200","article-title":"Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months","volume":"187","author":"McQuaid","year":"2015","journal-title":"CMAJ"},{"key":"10.1016\/j.jinf.2017.12.005_bib0160","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/INF.0000000000000327","article-title":"Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age","volume":"33","author":"McQuaid","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jinf.2017.12.005_bib0165","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.jinf.2017.12.005_bib0170","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jadohealth.2016.04.012","article-title":"The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines","volume":"59","author":"Pelton","year":"2016","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.jinf.2017.12.005_bib0175","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/cid\/cix154","article-title":"Impact of an immunization campaign to control an increased incidence of serogroup B meningococcal disease in one region of Quebec, Canada","volume":"64","author":"De Wals","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2017.12.005_bib0180","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S1473-3099(16)30314-0","article-title":"Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial","volume":"17","author":"Marshall","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2017.12.005_bib0185","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1086\/652765","article-title":"Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999\u20132000 and response to a booster: a phase 4 clinical trial","volume":"50","author":"Perrett","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2017.12.005_bib0190","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1016\/j.vaccine.2012.02.046","article-title":"Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations","volume":"30","author":"Khatami","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2017.12.005_bib0195","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/21645515.2015.1058457","article-title":"Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine","volume":"12","author":"Vesikari","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jinf.2017.12.005_bib0200","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1016\/j.vaccine.2013.07.083","article-title":"Effectiveness of meningococcal serogroup C vaccine programmes","volume":"31","author":"Borrow","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2017.12.005_bib0205","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial","volume":"384","author":"Read","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2017.12.005_bib0210","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.vaccine.2016.11.071","volume":"35","author":"Read","year":"2017","journal-title":"Vaccine"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445317304024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445317304024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:25:16Z","timestamp":1759008316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445317304024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0163445317304024"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2017.12.005","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody persistence and booster responses 24\u201336 months after different 4CMenB vaccination schedules in infants and children: A randomised trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2017.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 GlaxoSmithKline SA. Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}]}}